Search Results - "Ormaasen, V"

CYP3A induction and inhibition by different antiretroviral regimens reflected by changes in plasma 4β-hydroxycholesterol levels by Josephson, F., Bertilsson, L., Böttiger, Y., Flamholc, L., Gisslén, M., Ormaasen, V., Sönnerborg, A., Diczfalusy, U.

“…Objective and methods A member of the major human cytochrome P450 superfamily of hemoproteins, CYP3A4/5, converts cholesterol into 4β-hydroxycholesterol. We…”
Get full text

Drug resistance is widespread among children who receive long-term antiretroviral treatment at a rural Tanzanian hospital by Bratholm, Clara, Johannessen, Asgeir, Naman, Ezra, Gundersen, Svein G., Kivuyo, Sokoine L., Holberg-Petersen, Mona, Ormaasen, Vidar, Bruun, Johan N.

“…Objectives To assess long-term virological efficacy and the emergence of drug resistance in children who receive antiretroviral treatment (ART) in rural…”
Get full text

CYP3A induction and inhibition by different antiretroviral regimens reflected by changes in plasma 4beta-hydroxycholesterol levels by Josephson, F, Bertilsson, L, Böttiger, Y, Flamholc, L, Gisslén, M, Ormaasen, V, Sönnerborg, A, Diczfalusy, U

“…A member of the major human cytochrome P450 superfamily of hemoproteins, CYP3A4/5, converts cholesterol into 4beta-hydroxycholesterol. We studied plasma…”
Get full text

Immunoglobulin Levels Amongst Persons with and without Human Immunodeficiency Virus Type 1 Infection in Uganda and Norway by Lugada, E. S., Mermin, J., Asjo, B., Kaharuza, F., Downing, R., Langeland, N., Ormaasen, V., Bruun, J., Awor, A. C., Ulvestad, E.

“…CD4+‐cell count and viral load monitoring are expensive and unavailable to most human immunodeficiency virus (HIV)‐infected people in Africa. In an attempt to…”
Get full text

Infection‐related and ‐unrelated malignancies, HIV and the aging population by Borges, ÁH, Ledergerber, B, Domingo, P, Knysz, B, Karpov, I, Kirk, O, Lundgren, J, Clumeck, N., Vandekerckhove, L., Machala, L., Kronborg, G., Larsen, M., Gerstoft, J., Katzenstein, T., Skinhøj, P., Pedersen, C., Dragsted, U. B., Zilmer, K., Girard, P‐M., Vanhems, P., Pradier, C., Neau, D., Schmidt, R., Lunzen, J., Stellbrink, H. J., Bickel, M., Fätkenheuer, G., Kosmidis, J., Gargalianos, P., Perdios, J., Gottfredsson, M., Burke, M., Pollack, S., Hassoun, G., Haouzi, M., Esposito, R., Arici, C., Pristera, R., Mazzotta, F., Montesarchio, E., Gargiulo, M., D'Offizi, G., Taibi, C., Antinori, A., Lazzarin, A., Ridolfo, A., Chaplinskas, S., Reiss, P., Ormaasen, V., Boron‐Kaczmarska, A., Pynka, M., Parczewski, M., Mularska, E., Jablonowska, E., Wojcik, K., Doroana, M., Caldeira, L., Maltez, F., Duiculescu, D., Rakhmanova, A., Buzunova, S., Jevtovic, D., Mokráš, M., Staneková, D., Rodriguez, J. M., Bravo, I., Gatell, J. M., Medrano, J., Flamholc, L., Weber, R., Francioli, P., Cavassini, M., Boffi, E., Battegay, M., Elzi, L., Kravchenko, E., Frolov, V., Kutsyna, G., Servitskiy, S., Kuznetsova, A., Kyselyova, G., Simons, E., Orkin, C., Fisher, M., Horban, A., Pedersen, C., Rakhmanova, A., Phillips, A., Cozzi‐Lepri, A., Grint, D., Schultze, A., Raben, D., Kjær, J., Fischer, A. H., Grarup, J., Thiebaut, R., Burger, D., Paredes, R., Kjær, J., Peters, L.

“…Objectives HIV‐positive people have increased risk of infection‐related malignancies (IRMs) and infection‐unrelated malignancies (IURMs). The aim of the study…”
Get full text

Deteriorating renal function and clinical outcomes in HIV-positive persons by MOCROFT, Amanda, RYOM, Lene, BEGOVAC, Josip, D'ARMINIO MONFORTE, Antonella, VASSILENKO, Anne, GATELL, Jose, FLORENCE, Eric, ORMAASEN, Vidar, KIRK, Ole, LUNDGREN, Jens D

“…To determine the relationship between measures of renal function [current estimated glomerular filtration rate (eGFR) and proportion of follow-up with a low…”
Get full text

Where is the greatest impact of uncontrolled HIV infection on AIDS and non-AIDS events in HIV? by Mocroft, Amanda, Laut, Kamilla, Reiss, Peter, Gatell, Jose, Ormaasen, Vidar, Cavassini, Matthias, Hadziosmanovic, Vesna, Mansinho, Kamal, Pradier, Christian, Vasylyev, Marta, Mitsura, Victor, Vandekerckhove, Linos, Ostergaard, Lars, Clarke, Amanda, Degen, Olaf, Mulcahy, Fiona, Castagna, Antonella, Sthoeger, Zed, Flamholc, Leo, Sedláček, Dalibor, Mozer-Lisewska, Iwona, Lundgren, Jens D

“…OBJECTIVE:The extent to which controlled and uncontrolled HIV interact with ageing, European region of care and calendar year of follow-up is largely unknown…”
Get full text

Regional differences in AIDS and non-AIDS related mortality in HIV-positive individuals across Europe and Argentina: the EuroSIDA study by Reekie, Joanne, Kowalska, Justyna D, Karpov, Igor, Rockstroh, Jurgen, Karlsson, Anders, Rakhmanova, Aza, Horban, Andrzej, Kirk, Ole, Lundgren, Jens D, Mocroft, Amanda

“…Differences in access to care and treatment have been reported in Eastern Europe, a region with one of the fastest growing HIV epidemics, compared to the rest…”
Get full text

Incidence of cancer and overall risk of mortality in individuals treated with raltegravir‐based and non‐raltegravir‐based combination antiretroviral therapy regimens by Zangerle, R, Ristola, M, Pradier, C, Fätkenheuer, G, Gottfredsson, M, Jilich, D, Flisiak, R, Rozentale, B, Radoi, R, Losso, MH, Lundgren, JD, Mocroft, A, Schmied, B., Mitsura, V. M., Paduto, D., De Wit, S., Vandekerckhove, L., Hadziosmanovic, V., Begovac, J., Sedlacek, D., Kronborg, G., Gerstoft, J., Katzenstein, T., Møller, N. F., Ostergaard, L., Girard, P.‐M., Fontas, E., Stellbrink, H. J., Chkhartishvili, N., Xylomenos, G., Lourida, P., Szlávik, J., Mulcahy, F., Burke, M., Shahar, E., Hassoun, G., Elinav, H., Esposito, R., Mussini, C., Gabbuti, A., Lichtner, M., Plazzi, M., Gianotti, N., Matulionyte, R., Hemmer, R., Maeland, A., Bruun, J., Gasiorowski, J., Horban, A., Parczewski, M., Maciejewska, K., Mularska, E., Smiatacz, T., Oprea, C., Panteleev, A., Panteleev, O., Yakovlev, A., Kuzovatova, E., Borodulina, E., Vdoushkina, E., Tomazic, J., Gatell, J. M., Miró, J. M., Clotet, B., Paredes, R., Tural, C., Puig, J., Bravo, I., Domingo, P., Gutierrez, M., Mateo, G., Falconer, K., Thalme, A., Blaxhult, A., Scherrer, A., Weber, R., Cavassini, M., Calmy, A., Battegay, M., Kuznetsova, A., Kyselyova, G., Sluzhynska, M., Johnson, A. M., Simons, E., Edwards, S., Phillips, A., Johnson, M. A., Weber, J., Scullard, G., Leen, C., Thiebaut, R., Matthews, C., Fischer, A. H., Bojesen, A., Raben, D., Kristensen, D., Larsen, J. F., Podlekareva, D., Shepherd, L., Schultze, A.

“…Objectives There are currently few data on the long‐term risk of cancer and death in individuals taking raltegravir (RAL). The aim of this analysis was to…”
Get full text

The relation between treatment outcome and efavirenz, atazanavir or lopinavir exposure in the NORTHIV trial of treatment-na⟨ve HIV-1 infected patients by Josephson, F, Andersson, MCH, Flamholc, L, Gisslen, M, Hagberg, L, Ormaasen, V, Sonnerborg, A, Vesterbacka, J, Bottiger, Y

Get full text

Bilirubin—A Potential Marker of Drug Exposure in Atazanavir-Based Antiretroviral Therapy by Rekić, Dinko, Clewe, Oskar, Röshammar, Daniel, Flamholc, Leo, Sönnerborg, Anders, Ormaasen, Vidar, Gisslén, Magnus, Äbelö, Angela, Ashton, Michael

“…The objective of this work was to examine the atazanavir–bilirubin relationship using a population-based approach and to assess the possible application of…”
Get full text

relation between treatment outcome and efavirenz, atazanavir or lopinavir exposure in the NORTHIV trial of treatment-naïve HIV-1 infected patients by Josephson, Filip, Andersson, Maria C. H, Flamholc, Leo, Gisslén, Magnus, Hagberg, Lars, Ormaasen, Vidar, Sönnerborg, Anders, Vesterbacka, Jan, Böttiger, Ylva

“…Purpose The relation between treatment outcome and trough plasma concentrations of efavirenz (EFV), atazanavir (ATV) and lopinavir (LPV) was studied in a…”
Get full text

Factors associated with a reduced CD4 lymphocyte count response to HAART despite full viral suppression in the EuroSIDA study by Florence, E, Lundgren, J, Dreezen, C, Fisher, M, Kirk, O, Blaxhult, A, Panos, G, Katlama, C, Vella, S, Phillips, A

“…Objectives To describe the prevalence and risk factors of poor CD4 count rise despite a good virological response on highly active antiretroviral treatment…”
Get full text

A survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in Europe by Mocroft, A., Reiss, P., Rakhmanova, A., Banhegyi, D., Phillips, A. N., De Wit, S., Ristola, M., Lundgren, J. D., Grarup, J., Kirk, O.

“…ATRIPLA is licensed for use only in HIV-positive persons whose viral loads <50 for ≥3 months. We investigated the use of ATRIPLA as first-line antiretroviral…”
Get full text

CYP3A induction and inhibition by different antiretroviral regimens reflected by changes in plasma 4[beta]-hydroxycholesterol levels by Josephson, F, Bertilsson, L, Böttiger, Y, Flamholc, L, Gisslén, M, Ormaasen, V, Sönnerborg, A, Diczfalusy, U

“…A member of the major human cytochrome P450 superfamily of hemoproteins, CYP3A4/5, converts cholesterol into 4[beta]-hydroxycholesterol. We studied plasma…”
Get full text

Differential effects of efavirenz, lopinavir/r, and atazanavir/r on the initial viral decay rate in treatment naïve HIV-1-infected patients by Edén, Arvid, Andersson, Lars-Magnus, Andersson, Orjan, Flamholc, Leo, Josephson, Filip, Nilsson, Staffan, Ormaasen, Vidar, Svedhem, Veronica, Säll, Christer, Sönnerborg, Anders, Tunbäck, Petra, Gisslén, Magnus

“…Initial viral decay rate may be useful when comparing the relative potency of antiretroviral regimens. Two hundred twenty-seven ART-naïve patients were…”
Get more information

HIV type-1 drug resistance testing on dried blood spots is feasible and reliable in patients who fail antiretroviral therapy in rural Tanzania by Johannessen, Asgeir, Holberg-Petersen, Mona, Lövgaarden, Gunilla, Naman, Ezra, Ormaasen, Vidar, Matee, Mecky I, Gundersen, Svein G, Bruun, Johan N

“…HIV type-1 (HIV-1) drug resistance testing is rarely available in resource-limited settings because of high costs and stringent requirements for storage and…”
Get more information

Immune modulatory effects of cyclooxygenase type 2 inhibitors in HIV patients on combination antiretroviral treatment by KVALE, Dag, ORMAASEN, Vidar, KRAN, Anne-Marte Bakken, JOHANSSON, Carl Christian, AUKRUST, Pal, AANDAHL, Einar Martin, FRØLAND, Stig S, TASKEN, Kjetil

“…To examine the immune modulating effects of cyclooxygenase type 2 (COX-2) inhibitors (COX-2i) in HIV-infected patients on combination antiretroviral treatment…”
Get full text

Non-linear mixed effects modeling of antiretroviral drug response after administration of lopinavir, atazanavir and efavirenz containing regimens to treatment-naïve HIV-1 infected patients by Röshammar, Daniel, Simonsson, Ulrika S. H., Ekvall, Håkan, Flamholc, Leo, Ormaasen, Vidar, Vesterbacka, Jan, Wallmark, Eva, Ashton, Michael, Gisslén, Magnus

“…The objective of this analysis was to compare three methods of handling HIV-RNA data below the limit of quantification (LOQ) when describing the time-course of…”
Get full text

Thymidine analogue mutation profiles : factors associated with acquiring specific profiles and their impact on the virological response to therapy by COZZI-LEPRI, Alessandro, RUIZ, Lidia, LOVEDAY, Clive, PHILLIPS, Andrew N, CLOTET, Bonaventura, REISS, Peter, LEDERGERBER, Bruno, HOLKMANN, Christian, STASZEWSKI, Schlomo, LUNDGREN, Jens D

“…Studies have suggested that HIV-1 may develop thymidine analogue mutations (TAMs) by one of two distinct pathways - the TAM1 pathway (including mutations 41L,…”
Get full text